Search
Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigational[A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor.
Categories: Agents for Dermatitis, Excluding Corticosteroids, Cytochrome P-450 SubstratesLinvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigational[L53348][L53353] Linvoseltamab is indicated for adult patients with RRMM who have previously received at least three classes of therapy: a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 … By binding to both targets simultaneously, linvoseltamab redirects T cells toward myeloma cells, forming an immunological synapse that activates T-cell–mediated cytotoxicity.
Solifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigationalSolifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
Categories: Drugs for Urinary Frequency and Incontinence, Cytochrome P-450 SubstratesUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.[L10896]. … Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsAtazanavir
go.drugbank.com/drugs/DB01072ApprovedInvestigationalAtazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. … Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseSibeprenlimab
go.drugbank.com/drugs/DB18919ApprovedInvestigational[L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]
Methyl nicotinate
go.drugbank.com/drugs/DB13882ApprovedMethyl nicotinate is the methyl ester of [DB00627] that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain. … For veterinary purposes, methyl nicotinate is used to treat respiratory diseases, vascular disorders, rheumatoid arthritis, and muscle and joint pains [F64].
Mixtures: Arthricare for Women Nighttime, Arthricare for Women Multi-actionReserpine
go.drugbank.com/drugs/DB00206ApprovedWithdrawnThe FDA withdrew its approval for the use of all oral dosage form drug products containing more than 1 mg of reserpine.[L43942] … It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
Categories: Antihypertensive Agents Indicated for Hypertension, P-glycoprotein inducersAlendronic acid
go.drugbank.com/drugs/DB00630ApprovedInvestigationalAlendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111].
Categories: Drugs for Treatment of Bone DiseasesProducts: Ran-alendronate, Van-alendronatePucotenlimab
go.drugbank.com/drugs/DB17552ApprovedInvestigationalPucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours.
Synonyms: Humanized pd-1 blocking antibody hx-008